4021. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
作者: Bruce S Stambler.;A John Camm.;Marco Alings.;Paul Dorian.;Hein Heidbuchel.;Jaco Houtgraaf.;Peter R Kowey.;Jose L Merino.;Blandine Mondésert.;Jonathan P Piccini.;Sean D Pokorney.;Philip T Sager.;Atul Verma.;J Marcus Wharton.;David B Bharucha.;Francis Plat.;Silvia Shardonofsky.;Michael Chen.;James E Ip.; .
来源: Lancet. 2023年402卷10396期118-128页
Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for on-demand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. We aimed to evaluate the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 min.
4024. Health outcomes of the G7 Hiroshima Summit: breaking the cycle of panic and neglect and achieving UHC.
作者: Satoshi Ezoe.;Jin Hashimoto.;Yuichiro Nishida.;Hokuto Namikawa.;Makiko Yoneda.;Satomi Ichino.;Sae Tanaka.;Takahiro Ohmori.;Maiko Oya.;Natsuko Hatano.;Eiji Hinoshita.;Keiichi Hara.;Naoki Ito.;Takeshi Akahori.
来源: Lancet. 2023年401卷10394期2091-2093页 |